Both activating and inhibiting components have been reported to harbor variants that potentially have functional impacts on the AP (Table 4), with an increase in overall mutational burden being reported in CFH and CFI in AMD patients [60, 83]. The gene discussed is CFI; the disease is age-related macular degeneration.